Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 1
2016 1
2017 1
2018 3
2019 14
2020 9
2021 10
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

39 results
Results by year
Filters applied: . Clear all
Page 1
eEF2K: an atypical kinase target for cancer.
Temme L, Asquith CRM. Temme L, et al. Among authors: asquith crm. Nat Rev Drug Discov. 2021 Aug;20(8):577. doi: 10.1038/d41573-021-00124-5. Nat Rev Drug Discov. 2021. PMID: 34257429 No abstract available.
RIOK2: straddling the kinase/ATPase line.
Asquith CRM, East MP, Zuercher WJ. Asquith CRM, et al. Nat Rev Drug Discov. 2019 Jul;18(8):574. doi: 10.1038/d41573-019-00107-7. Nat Rev Drug Discov. 2019. PMID: 31367048 No abstract available.
PKMYT1: a forgotten member of the WEE1 family.
Asquith CRM, Laitinen T, East MP. Asquith CRM, et al. Nat Rev Drug Discov. 2020 Mar;19(3):157. doi: 10.1038/d41573-019-00202-9. Nat Rev Drug Discov. 2020. PMID: 32127662 No abstract available.
STK19: a new target for NRAS-driven cancer.
Asquith CRM, Temme L. Asquith CRM, et al. Nat Rev Drug Discov. 2020 Sep;19(9):579. doi: 10.1038/d41573-020-00116-x. Nat Rev Drug Discov. 2020. PMID: 32587355 No abstract available.
39 results